scispace - formally typeset
Open AccessJournal ArticleDOI

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

TLDR
This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
Abstract
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

read more

Citations
More filters
Posted ContentDOI

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

TL;DR: In this article , a human monoclonal antibody, 87G7, was proposed to achieve broad neutralization and protection against Omicron and other SARS-CoV-2 variants.
Posted ContentDOI

Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of the fixation of selected mutations

TL;DR: In this paper, the effect of positively selected mutations fixed in the Brazilian SARS-CoV-2 lineages and to check for mutational evidence of coevolution was evaluated by estimating the binding affinity in the RBD-hACE2 complex.
Journal ArticleDOI

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

TL;DR: In this paper, a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein of SARS-CoV-2 was generated through traditional mouse immunization.
Journal ArticleDOI

It is never too late for a cocktail - Development and analytical characterization of fixed-dose antibody combinations.

TL;DR: In this article , the authors summarize the recent progress on antibody fixed-dose combinations with a focus on important considerations during drug development and the analytical toolbox for co-formulated mAbs.
Journal ArticleDOI

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

TL;DR: In this paper , the authors summarized the progress of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS CoV, and MERS CoV and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.
References
More filters
Journal ArticleDOI

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

TL;DR: Cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein of SARS-CoV-2 are presented, providing important insights into the molecular basis for coronavirus recognition and infection.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Journal ArticleDOI

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Related Papers (5)